{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:30:12Z","timestamp":1791379812611,"version":"4.3.3"},"reference-count":15,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Ms. K is a 34-year-old female, gravida 1, para 1 (G1P1001) with a psychiatric history of major depressive disorder, previously managed with bupropion in her early 20s. Following delivery of her child, she developed symptoms of generalized anxiety disorder with panic attacks. Ms. K subsequently developed intrusive thoughts related to the health and well-being of her child, that morphed into intrusive, unwanted thoughts about aggression and harm towards her baby and began avoiding contact with her infant due to fear and guilt. Bupropion was restarted by her primary care clinician, due to her past response, but was only mildly helpful. She was referred to Psychiatry and diagnosed with obsessive compulsive disorder (OCD). Patient Health Questionnaire-9 (PHQ-9) screening score was 11 and Generalized Anxiety Disorder-7 (GAD-7) screening score was 13 at her initial visit. Bupropion was discontinued in favor of sertraline and addition of cognitive behavioral therapy (CBT) with an exposure response prevention (ERP) approach was also recommended.<\/jats:p>","DOI":"10.64719\/pb.4422","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"117-121","source":"Crossref","is-referenced-by-count":3,"title":["Dose-Dependent Urinary Incontinence with Sertraline Use in Obsessive-Compulsive Disorder"],"prefix":"10.64719","volume":"51","author":[{"given":"Eric","family":"Pease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balwinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ziegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Betcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Palma I-AF, Staack A. Impact of Caffeine on Overactive Bladder Symptoms. Current Bladder Dysfunction Reports. 2016;11:1\u20137.","DOI":"10.1007\/s11884-016-0342-y"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Townsend MK, Resnick NM, Grodstein F. Caffeine intake and risk of urinary incontinence progression among women. Obstetrics and gynecology. 2012;119:950\u2013957.","DOI":"10.1097\/AOG.0b013e31824fc604"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Movig KL, Leufkens HG, Belitser SV, Lenderink AW, Egberts AC. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf. 2002;11:271\u2013279.","DOI":"10.1002\/pds.705"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Solmaz V, Albayrak S, Tekatas A, Aksoy D, Gen\u00e7ten Y, \u0130nan\u0131r S, Erdemir F. Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study. Int Neurourol J. 2017;21:62\u201367.","DOI":"10.5213\/inj.1732652.326"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Polimeni G, Salvo F, Cutroneo P, Nati G, Russo A, Giustini ES, Spina E. Venlafaxine-induced urinary incontinence resolved after switching to sertraline. Clin Neuropharmacol. 2005;28:247\u2013248.","DOI":"10.1097\/01.wnf.0000188205.25750.2d"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11:386\u2013388.","DOI":"10.1007\/s001920070009"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cavanaugh GL, Martin RE, Stenson MA, Robinson DD. Venlafaxine and urinary incontinence: possible association. Ann Pharmacother. 1997;31:372.","DOI":"10.1177\/106002809703100321"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Hansen LK. Venlafaxine-induced increase in urinary frequency in 3 women. J Clin Psychiatry. 2004;65:877\u2013878.","DOI":"10.4088\/JCP.v65n0622a"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Tonini M, Messori E, Franceschetti GP, Rizzi CA, Castoldi AF, Coccini T, Candura SM. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. British Journal of Pharmacology. 1994;113:1\u20132.","DOI":"10.1111\/j.1476-5381.1994.tb16163.x"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Andersson KE. Treatment of the overactive bladder: possible central nervous system drug targets. Urology. 2002;59:18\u201324.","DOI":"10.1016\/S0090-4295(01)01634-X"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249\u2013258.","DOI":"10.1016\/S0014-2999(97)01393-9"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17042\u201317042.","DOI":"10.1038\/nrdp.2017.42"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Pampaloni I, Sivakumaran T, Hawley C, Al Allaq A, Farrow J, Nelson S, Fineberg N. High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. Journal of Psychopharmacology. 2010;24:1439\u20131445.","DOI":"10.1177\/0269881109104850"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry. 2010;15:850\u2013855.","DOI":"10.1038\/mp.2009.50"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Sigurdardottir T, Steingrimsdottir T, Geirsson RT, Halldorsson TI, Aspelund T, B\u00f8 K. Can postpartum pelvic floor muscle training reduce urinary and anal incontinence?: An assessor-blinded randomized controlled trial. Am J Obstet Gynecol. 2020;222:247.e241\u2013247.e248.","DOI":"10.1016\/j.ajog.2019.09.011"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:29:54Z","timestamp":1791314994000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/dose-dependent-urinary-incontinence-with-sertraline-use-in-obsessive-compulsive-disorder\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4422","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}